Overview: Fecal Calprotectin TestIntroduction: The Fecal Calprotectin Test measures calprotectin in stool to detect inflammatory bowel diseases, causing diarrhea or abdominal pain. Aligned with 2023 ACG guidelines, it uses an immunoassay for high sensitivity, aiding in inflammatory screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected IBD.
Other Names: Fecal Calprotectin Assay, IBD Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Fecal calprotectin testing began in the 1990s with IBD research. Immunoassays emerged in the 2000s, improving accuracy for inflammatory marker detection.
Purpose: Diagnoses inflammatory bowel diseases, guides treatment, and monitors calprotectin levels in patients with diarrhea or abdominal pain.
Test Parameters: 1. Calprotectin
Pretest Condition: Fasting for 10-12 hours required to stabilize results. Collect stool at any time. Report symptoms like diarrhea or abdominal pain, and list medications like anti-inflammatories.
Specimen: 5-10 g stool (sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document diarrhea, abdominal pain, or history of IBD (e.g., Crohn's, ulcerative colitis). Include current medications, especially anti-inflammatories.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for IBD therapy.
Procedural Considerations: Uses an immunoassay to measure fecal calprotectin levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting, contamination, or medications can affect results. Non-IBD inflammation may elevate levels.
Clinical Significance: Elevated calprotectin levels suggest IBD, prompting treatment or colonoscopy. Normal levels may require further testing.
Specialist Consultation: Consult a gastroenterologist for result interpretation.
Additional Supporting Tests: Colonoscopy, CRP, or stool culture to confirm IBD.
Test Limitations: Non-specific elevations may occur in non-IBD conditions. Results require clinical correlation.
References: ACG IBD Guidelines, 2023; Gastroenterology, Sands BE, 2022.
